A Study to Evaluate the Safety and Efficacy of Sorafenib Maintenance after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients With FLT3-ITD Acute Myeloid Leukemia (AML)

Trial Profile

A Study to Evaluate the Safety and Efficacy of Sorafenib Maintenance after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients With FLT3-ITD Acute Myeloid Leukemia (AML)

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Apr 2017 Results published in the Cancer
    • 03 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top